The term cirrhosis-associated immune dysfunction (CAID) comprises the distinctive
spectrum of immune alterations associated with the course of end-stage liver disease …

Hepatocellular carcinoma (HCC) is the third leading cause of worldwide cancer mortality.
HCC almost exclusively develops in patients with chronic liver disease, driven by a vicious …

This AASLD Guidance provides a data-supported approach to the management of ascites
and HRS. It differs from the AASLD Guidelines, which are supported by systematic reviews …

Background & Aims Acute decompensation (AD) of cirrhosis may present without acute-on-
chronic liver failure (ACLF)(AD-No ACLF), or with ACLF (AD-ACLF), defined by organ failure …

The natural history of cirrhosis is characterised by an asymptomatic compensated phase
followed by a decompensated phase, marked by the development of overt clinical signs, the …

Background & Aims Bacterial infections are common and life-threatening in patients with
cirrhosis. Little is known about the epidemiology of bacterial infections in different regions …

The clinical course of cirrhosis is mostly determined by the progressive increase of portal
hypertension, hyperdynamic circulation, bacterial translocation and activation of systemic …

Background & Aims We performed a prospective study to investigate the effects of a
sustained viral response (SVR) on outcomes of patients with hepatitis C virus (HCV) …

Background & Aims Antibiotic resistance has been increasingly reported in patients with
decompensated cirrhosis in single-center studies. Prospective investigations reporting …

Bacterial infections are frequent in cirrhotic patients with acute decompensation or acute-on-
chronic liver failure and can complicate the clinical course. Delayed diagnosis and …